TOP TEN perturbations for 38763_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38763_at
Selected probe(set): 230782_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38763_at (230782_at) across 6674 perturbations tested by GENEVESTIGATOR:

skin squamous cell carcinoma study 6 / basal cell carcinoma study 2

Relative Expression (log2-ratio):-3.4754047
Number of Samples:4 / 2
Experimental skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

HCC study 9 (alcohol; HBV) / HCC study 9 (HBV)

Relative Expression (log2-ratio):3.101489
Number of Samples:3 / 10
Experimental HCC study 9 (alcohol; HBV)
Liver tissue biopsy sample from patients with alcohol abuse and Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.
Control HCC study 9 (HBV)
Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.

pancreatic cancer study 3 (ipmn) / normal pancreas tissue

Relative Expression (log2-ratio):3.0346937
Number of Samples:3 / 6
Experimental pancreatic cancer study 3 (ipmn)
Intraductal papillary mucinous neoplasm from patients with pancreatic cancer.
Control normal pancreas tissue
Normal human pancreatic tissue.

adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):2.8030014
Number of Samples:3 / 21
Experimental adefovir study 1 (50uM)
HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.6694727
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-2.6510172
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

pancreatic cancer study 3 (ipmn) / pancreatic cancer study 3 (ipma)

Relative Expression (log2-ratio):2.6491814
Number of Samples:3 / 6
Experimental pancreatic cancer study 3 (ipmn)
Intraductal papillary mucinous neoplasm from patients with pancreatic cancer.
Control pancreatic cancer study 3 (ipma)
Intraductal papillary mucinous adenoma from patients with pancreatic cancer.

brefeldin A study 1 (0.5ug/ml; HCT 116) / tunicamycin study 2 (2ug/ml; HCT 116)

Relative Expression (log2-ratio):-2.6177788
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---

prostate cancer study 1 (meta.) / benign prostate tissue

Relative Expression (log2-ratio):-2.5361671
Number of Samples:6 / 6
Experimental prostate cancer study 1 (meta.)
Metastatic prostate cancer samples.
Control benign prostate tissue
Benign prostate samples.

Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2

Relative Expression (log2-ratio):-2.5108624
Number of Samples:19 / 2
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

Organism: Homo sapiens
Gene: 38763_at
Selected probe(set): 201563_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38763_at (201563_at) across 6674 perturbations tested by GENEVESTIGATOR:

prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)

Relative Expression (log2-ratio):4.987013
Number of Samples:3 / 2
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):4.453725
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):3.9006996
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):3.531722
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):-3.454461
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-3.4037666
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-3.2914543
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-3.2827568
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

brefeldin A study 1 (0.5ug/ml; HCT 116) / tunicamycin study 2 (2ug/ml; HCT 116)

Relative Expression (log2-ratio):-3.1420107
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---

expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):3.1133842
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.